Pharma Reaserch Prod Co Ltd (214450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩61.53 Billion ≈ $41.70 Million USD) by net assets (₩723.88 Billion ≈ $490.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 214450 equity financing ratio to measure how much of total assets are equity-financed.
Pharma Reaserch Prod Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Pharma Reaserch Prod Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Pharma Reaserch Prod Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Pharma Reaserch Prod Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
-0.028x |
|
AstraZeneca PLC
LSE:AZN
|
0.071x |
|
Nektar Therapeutics
NASDAQ:NKTR
|
-0.077x |
|
Pfizer Limited
NSE:PFIZER
|
0.143x |
|
eToro Group Ltd.
NASDAQ:ETOR
|
0.076x |
|
Yantai Eddie Precision Mach
SHG:603638
|
0.058x |
|
BRP Inc.
NASDAQ:DOO
|
0.606x |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Pharma Reaserch Prod Co Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Pharma Reaserch Prod Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩723.88 Billion ≈ $490.56 Million |
₩183.16 Billion ≈ $124.13 Million |
0.253x | +3.01% |
| 2024-12-31 | ₩569.44 Billion ≈ $385.90 Million |
₩139.88 Billion ≈ $94.79 Million |
0.246x | +74.82% |
| 2023-12-31 | ₩462.19 Billion ≈ $313.22 Million |
₩64.95 Billion ≈ $44.01 Million |
0.141x | -18.75% |
| 2022-12-31 | ₩343.50 Billion ≈ $232.79 Million |
₩59.40 Billion ≈ $40.26 Million |
0.173x | -19.11% |
| 2021-12-31 | ₩305.44 Billion ≈ $206.99 Million |
₩65.30 Billion ≈ $44.25 Million |
0.214x | +61.97% |
| 2020-12-31 | ₩245.42 Billion ≈ $166.32 Million |
₩32.39 Billion ≈ $21.95 Million |
0.132x | +43.18% |
| 2019-12-31 | ₩209.07 Billion ≈ $141.69 Million |
₩19.27 Billion ≈ $13.06 Million |
0.092x | +250.09% |
| 2018-12-31 | ₩197.62 Billion ≈ $133.93 Million |
₩5.20 Billion ≈ $3.53 Million |
0.026x | -44.96% |
| 2017-12-31 | ₩178.85 Billion ≈ $121.21 Million |
₩8.56 Billion ≈ $5.80 Million |
0.048x | +0.60% |
| 2016-12-31 | ₩171.64 Billion ≈ $116.32 Million |
₩8.16 Billion ≈ $5.53 Million |
0.048x | -53.49% |
| 2015-12-31 | ₩156.75 Billion ≈ $106.23 Million |
₩16.02 Billion ≈ $10.86 Million |
0.102x | -- |
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more